ScreenerHero

URGN UroGen Pharma Ltd.

NAS · US · Healthcare · Biotechnology · urogen.com
40.70USD-1.76%Mkt Cap: 1.99B $P/E: —

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse therm…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap1.99B USD
Enterprise Value2.11B USD
Revenue (TTM)188.73M USD
Gross Profit97.34M USD
Net Income (TTM)-153.49M USD
Revenue/Share3.81 USD
Last Price40.70 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees300
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)14.83
PEG—
EV/EBITDA-31.85
EV/Revenue11.20
P/S10.73
P/B-15.29
EPS (TTM)-1.97
EPS (Forward)2.79
52W Range
15.8671% of range50.81
52W High50.81 USD
52W Low15.86 USD
Profitability
Gross Margin88.66%
Oper. Margin0.15%
EBITDA Margin-35.15%
Profit Margin-139.81%
ROE145.53%
ROA-76.57%
Growth
Revenue Growth199.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-162.44M USD
CapEx (TTM)289.00K USD
FCF Margin-56.68%
FCF Yield-5.38%
Net Debt88.15M USD
Net Debt/EBITDA-1.33
Balance Sheet
Debt/Equity-1.22
Current Ratio3.80
Quick Ratio3.18
Book Value/Sh-2.71 USD
Cash/Share2.21 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)60.00 USD
Upside (mean)+47.4%
Target Range48.00 USD – 75.00 USD
48.00+47.4% to mean75.00
# Analysts8
Ownership
Shares Out.48.88M
Float43.41M
Insiders3.49%
Institutions97.81%
Short Interest
Short Ratio7.6d
Short % Float13.04%
Short % Out.12.78%
Shares Short6.25M
Short (prev mo.)5.12M
Technical
SMA 5043.86 (-7.2%)
SMA 20030.02 (+35.6%)
Beta1.58
S&P 52W Chg16.45%
Avg Vol (30d)788.12K
Avg Vol (10d)837.12K
Technical Indicators
RSI (14)43.0
MACD-0.6539
MACD Signal-0.5764
MACD Hist.-0.0775
BB Upper44.60 USD
BB Middle42.04 USD
BB Lower39.49 USD
BB Width12.18%
ATR (14)1.932 USD
Vol Ratio (20d)0.63x